Serveur d'exploration sur les relations entre la France et l'Australie

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results

Identifieur interne : 008746 ( Main/Exploration ); précédent : 008745; suivant : 008747

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results

Auteurs : Sharon E. Plon [États-Unis] ; Diana M. Eccles [Royaume-Uni] ; Douglas Easton [Royaume-Uni] ; William D. Foulkes [Canada] ; Maurizio Genuardi [Italie] ; Marc S. Greenblatt [États-Unis] ; Frans B. L. Hogervorst [Pays-Bas] ; Nicoline Hoogerbrugge [Pays-Bas] ; Amanda B. Spurdle [Australie] ; Sean V. Tavtigian [France]

Source :

RBID : ISTEX:30C3DB41661CBDFE24A2E9FA25E30AC26F93A1B7

Descripteurs français

English descriptors

Abstract

Genetic testing of cancer susceptibility genes is now widely applied in clinical practice to predict risk of developing cancer. In general, sequence‐based testing of germline DNA is used to determine whether an individual carries a change that is clearly likely to disrupt normal gene function. Genetic testing may detect changes that are clearly pathogenic, clearly neutral, or variants of unclear clinical significance. Such variants present a considerable challenge to the diagnostic laboratory and the receiving clinician in terms of interpretation and clear presentation of the implications of the result to the patient. There does not appear to be a consistent approach to interpreting and reporting the clinical significance of variants either among genes or among laboratories. The potential for confusion among clinicians and patients is considerable and misinterpretation may lead to inappropriate clinical consequences. In this article we review the current state of sequence‐based genetic testing, describe other standardized reporting systems used in oncology, and propose a standardized classification system for application to sequence‐based results for cancer predisposition genes. We suggest a system of five classes of variants based on the degree of likelihood of pathogenicity. Each class is associated with specific recommendations for clinical management of at‐risk relatives that will depend on the syndrome. We propose that panels of experts on each cancer predisposition syndrome facilitate the classification scheme and designate appropriate surveillance and cancer management guidelines. The international adoption of a standardized reporting system should improve the clinical utility of sequence‐based genetic tests to predict cancer risk. Hum Mutat 29(11), 1282–1291, 2008. © 2008 Wiley‐Liss, Inc.

Url:
DOI: 10.1002/humu.20880


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results</title>
<author>
<name sortKey="Plon, Sharon E" sort="Plon, Sharon E" uniqKey="Plon S" first="Sharon E." last="Plon">Sharon E. Plon</name>
</author>
<author>
<name sortKey="Eccles, Diana M" sort="Eccles, Diana M" uniqKey="Eccles D" first="Diana M." last="Eccles">Diana M. Eccles</name>
</author>
<author>
<name sortKey="Easton, Douglas" sort="Easton, Douglas" uniqKey="Easton D" first="Douglas" last="Easton">Douglas Easton</name>
</author>
<author>
<name sortKey="Foulkes, William D" sort="Foulkes, William D" uniqKey="Foulkes W" first="William D." last="Foulkes">William D. Foulkes</name>
</author>
<author>
<name sortKey="Genuardi, Maurizio" sort="Genuardi, Maurizio" uniqKey="Genuardi M" first="Maurizio" last="Genuardi">Maurizio Genuardi</name>
</author>
<author>
<name sortKey="Greenblatt, Marc S" sort="Greenblatt, Marc S" uniqKey="Greenblatt M" first="Marc S." last="Greenblatt">Marc S. Greenblatt</name>
</author>
<author>
<name sortKey="Hogervorst, Frans B L" sort="Hogervorst, Frans B L" uniqKey="Hogervorst F" first="Frans B. L." last="Hogervorst">Frans B. L. Hogervorst</name>
</author>
<author>
<name sortKey="Hoogerbrugge, Nicoline" sort="Hoogerbrugge, Nicoline" uniqKey="Hoogerbrugge N" first="Nicoline" last="Hoogerbrugge">Nicoline Hoogerbrugge</name>
</author>
<author>
<name sortKey="Spurdle, Amanda B" sort="Spurdle, Amanda B" uniqKey="Spurdle A" first="Amanda B." last="Spurdle">Amanda B. Spurdle</name>
</author>
<author>
<name sortKey="Tavtigian, Sean V" sort="Tavtigian, Sean V" uniqKey="Tavtigian S" first="Sean V." last="Tavtigian">Sean V. Tavtigian</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:30C3DB41661CBDFE24A2E9FA25E30AC26F93A1B7</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/humu.20880</idno>
<idno type="url">https://api.istex.fr/document/30C3DB41661CBDFE24A2E9FA25E30AC26F93A1B7/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000935</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000935</idno>
<idno type="wicri:Area/Istex/Curation">000935</idno>
<idno type="wicri:Area/Istex/Checkpoint">001113</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001113</idno>
<idno type="wicri:doubleKey">1059-7794:2008:Plon S:sequence:variant:classification</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075918</idno>
<idno type="RBID">PMC:3075918</idno>
<idno type="wicri:Area/Pmc/Corpus">001478</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001478</idno>
<idno type="wicri:Area/Pmc/Curation">001338</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001338</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002922</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002922</idno>
<idno type="wicri:Area/Ncbi/Merge">000469</idno>
<idno type="wicri:Area/Ncbi/Curation">000469</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000469</idno>
<idno type="wicri:doubleKey">1059-7794:2008:Plon S:sequence:variant:classification</idno>
<idno type="wicri:Area/Main/Merge">009007</idno>
<idno type="wicri:Area/Main/Curation">008746</idno>
<idno type="wicri:Area/Main/Exploration">008746</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results
<ref type="note" target="#fn1"></ref>
</title>
<author>
<name sortKey="Plon, Sharon E" sort="Plon, Sharon E" uniqKey="Plon S" first="Sharon E." last="Plon">Sharon E. Plon</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Pediatrics, Baylor Cancer Genetics Clinic, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Molecular and Human Genetics, Baylor Cancer Genetics Clinic, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">États-Unis</country>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Texas</region>
</placeName>
<wicri:cityArea>Correspondence address: FACMG, MC3‐3320; 6621 Fannin St., Houston</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Eccles, Diana M" sort="Eccles, Diana M" uniqKey="Eccles D" first="Diana M." last="Eccles">Diana M. Eccles</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Medicine, University of Southampton, Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton</wicri:regionArea>
<wicri:noRegion>Southampton</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Easton, Douglas" sort="Easton, Douglas" uniqKey="Easton D" first="Douglas" last="Easton">Douglas Easton</name>
<affiliation wicri:level="4">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge</wicri:regionArea>
<orgName type="university">Université de Cambridge</orgName>
<placeName>
<settlement type="city">Cambridge</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Angleterre de l'Est</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Foulkes, William D" sort="Foulkes, William D" uniqKey="Foulkes W" first="William D." last="Foulkes">William D. Foulkes</name>
<affiliation wicri:level="4">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec</wicri:regionArea>
<orgName type="university">Université McGill</orgName>
<placeName>
<settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Genuardi, Maurizio" sort="Genuardi, Maurizio" uniqKey="Genuardi M" first="Maurizio" last="Genuardi">Maurizio Genuardi</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Medical Genetics Unit, Department of Clinical Pathophysiology, University of Florence, Florence</wicri:regionArea>
<wicri:noRegion>Florence</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Fiorgen Foundation for Pharmacogenomics, Sesto Fiorentino</wicri:regionArea>
<wicri:noRegion>Sesto Fiorentino</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Greenblatt, Marc S" sort="Greenblatt, Marc S" uniqKey="Greenblatt M" first="Marc S." last="Greenblatt">Marc S. Greenblatt</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Vermont</region>
</placeName>
<wicri:cityArea>Department of Medicine and Vermont Cancer Center, University of Vermont College of Medicine, Burlington</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Hogervorst, Frans B L" sort="Hogervorst, Frans B L" uniqKey="Hogervorst F" first="Frans B. L." last="Hogervorst">Frans B. L. Hogervorst</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>DNA‐Diagnostic Laboratory of the Family Cancer Clinic, Department of Pathology, The Netherlands Cancer Institute, Amsterdam</wicri:regionArea>
<placeName>
<settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hoogerbrugge, Nicoline" sort="Hoogerbrugge, Nicoline" uniqKey="Hoogerbrugge N" first="Nicoline" last="Hoogerbrugge">Nicoline Hoogerbrugge</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Human Genetics, Radboud University Medical Center, Nijmegen</wicri:regionArea>
<placeName>
<settlement type="city">Nimègue</settlement>
<region type="province" nuts="2">Gueldre</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Spurdle, Amanda B" sort="Spurdle, Amanda B" uniqKey="Spurdle A" first="Amanda B." last="Spurdle">Amanda B. Spurdle</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Genetics and Population Health Division, Queensland Institute of Medical Research, Brisbane</wicri:regionArea>
<wicri:noRegion>Brisbane</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Tavtigian, Sean V" sort="Tavtigian, Sean V" uniqKey="Tavtigian S" first="Sean V." last="Tavtigian">Sean V. Tavtigian</name>
<affiliation wicri:level="1">
<country xml:lang="fr">France</country>
<wicri:regionArea>International Agency for Research on Cancer; Lyon</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Human Mutation</title>
<title level="j" type="sub">Special Issue: Assessing Mutation Pathogenicity in Cancer Susceptibility Genes</title>
<title level="j" type="alt">HUMAN MUTATION</title>
<idno type="ISSN">1059-7794</idno>
<idno type="eISSN">1098-1004</idno>
<imprint>
<biblScope unit="vol">29</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1282">1282</biblScope>
<biblScope unit="page" to="1291">1291</biblScope>
<biblScope unit="page-count">10</biblScope>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-11">2008-11</date>
</imprint>
<idno type="ISSN">1059-7794</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1059-7794</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>American college</term>
<term>Assay</term>
<term>Association study</term>
<term>Baylor cancer genetics clinic</term>
<term>Baylor college</term>
<term>Birads classification</term>
<term>Birads system</term>
<term>Brca1</term>
<term>Brca2</term>
<term>Brca2 gene</term>
<term>Brca2 testing</term>
<term>Breast cancer</term>
<term>Breast cancer information core</term>
<term>Canadian breast cancer research alliance</term>
<term>Cancer</term>
<term>Cancer association</term>
<term>Cancer facts</term>
<term>Cancer genetics</term>
<term>Cancer research</term>
<term>Cancer risk</term>
<term>Cancer risk assessment</term>
<term>Cancer susceptibility</term>
<term>Cancer susceptibility genes</term>
<term>Cancer syndromes</term>
<term>Carcinogenicity</term>
<term>Classification category</term>
<term>Classification system</term>
<term>Clinical advice</term>
<term>Clinical classification</term>
<term>Clinical geneticists</term>
<term>Clinical interpretation</term>
<term>Clinical management</term>
<term>Clinical practice</term>
<term>Clinical recommendations</term>
<term>Clinical significance</term>
<term>Clinical testing</term>
<term>Clinical utilization</term>
<term>Clinician</term>
<term>Colon cancer</term>
<term>Colorectal</term>
<term>Colorectal cancer</term>
<term>Common polymorphisms</term>
<term>Computational methods</term>
<term>Cumulative lifetime</term>
<term>Cumulative lifetime breast cancer risk</term>
<term>Cumulative risk</term>
<term>Data system</term>
<term>Database</term>
<term>Easton</term>
<term>Ente cassa</term>
<term>Expert panels</term>
<term>Family history</term>
<term>Family member</term>
<term>Family members</term>
<term>Further data</term>
<term>Gene</term>
<term>Gene function</term>
<term>Gene variants</term>
<term>General population</term>
<term>Genet</term>
<term>Genetic</term>
<term>Genetic testing</term>
<term>Genetic tests</term>
<term>Genetic variants</term>
<term>Genetics</term>
<term>Genetics service</term>
<term>Goldgar</term>
<term>Greenblatt</term>
<term>Guideline</term>
<term>High probability</term>
<term>High risk</term>
<term>Hnpcc</term>
<term>Human genetics</term>
<term>Human mutation</term>
<term>Iarc</term>
<term>Inactivating mutations</term>
<term>Lake champlain cancer research organization</term>
<term>Lifetime risk</term>
<term>Likelihood ratio</term>
<term>Likely explanation</term>
<term>Lower limit</term>
<term>Mcgill university</term>
<term>Medical research</term>
<term>Missense substitutions</term>
<term>Mlh1</term>
<term>Multiple lines</term>
<term>Mutat</term>
<term>Mutation</term>
<term>Mutation carrier</term>
<term>Netherlands cancer institute</term>
<term>Odds ratios</term>
<term>Other genes</term>
<term>Other risk factors</term>
<term>Other types</term>
<term>Ovarian</term>
<term>Ovarian cancer</term>
<term>Pathogenic</term>
<term>Pathogenic mutation</term>
<term>Pathogenicity</term>
<term>Polygenic factors</term>
<term>Population risk</term>
<term>Posterior odds</term>
<term>Posterior probability</term>
<term>Predictive testing</term>
<term>Predictive values</term>
<term>Proband</term>
<term>Queensland institute</term>
<term>Research council</term>
<term>Residual</term>
<term>Residual risk</term>
<term>Risparmio firenze</term>
<term>Routine screening</term>
<term>Second family member</term>
<term>Segregation analysis</term>
<term>Sequence changes</term>
<term>Sequence conservation</term>
<term>Sequence variant</term>
<term>Sequence variants</term>
<term>Sequence variations</term>
<term>Steering committee</term>
<term>Such variants</term>
<term>Surveillance guidelines</term>
<term>Susceptibility</term>
<term>Syndrome</term>
<term>Systematic review</term>
<term>Tavtigian</term>
<term>Test result</term>
<term>Triple assessment</term>
<term>Tumor pathology</term>
<term>Uncertain variants</term>
<term>Variant</term>
<term>Variant result</term>
<term>Variant segregates</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>American college</term>
<term>Assay</term>
<term>Association study</term>
<term>Baylor cancer genetics clinic</term>
<term>Baylor college</term>
<term>Birads classification</term>
<term>Birads system</term>
<term>Brca1</term>
<term>Brca2</term>
<term>Brca2 gene</term>
<term>Brca2 testing</term>
<term>Breast cancer</term>
<term>Breast cancer information core</term>
<term>Canadian breast cancer research alliance</term>
<term>Cancer</term>
<term>Cancer association</term>
<term>Cancer facts</term>
<term>Cancer genetics</term>
<term>Cancer research</term>
<term>Cancer risk</term>
<term>Cancer risk assessment</term>
<term>Cancer susceptibility</term>
<term>Cancer susceptibility genes</term>
<term>Cancer syndromes</term>
<term>Carcinogenicity</term>
<term>Classification category</term>
<term>Classification system</term>
<term>Clinical advice</term>
<term>Clinical classification</term>
<term>Clinical geneticists</term>
<term>Clinical interpretation</term>
<term>Clinical management</term>
<term>Clinical practice</term>
<term>Clinical recommendations</term>
<term>Clinical significance</term>
<term>Clinical testing</term>
<term>Clinical utilization</term>
<term>Clinician</term>
<term>Colon cancer</term>
<term>Colorectal</term>
<term>Colorectal cancer</term>
<term>Common polymorphisms</term>
<term>Computational methods</term>
<term>Cumulative lifetime</term>
<term>Cumulative lifetime breast cancer risk</term>
<term>Cumulative risk</term>
<term>Data system</term>
<term>Database</term>
<term>Easton</term>
<term>Ente cassa</term>
<term>Expert panels</term>
<term>Family history</term>
<term>Family member</term>
<term>Family members</term>
<term>Further data</term>
<term>Gene</term>
<term>Gene function</term>
<term>Gene variants</term>
<term>General population</term>
<term>Genet</term>
<term>Genetic</term>
<term>Genetic testing</term>
<term>Genetic tests</term>
<term>Genetic variants</term>
<term>Genetics</term>
<term>Genetics service</term>
<term>Goldgar</term>
<term>Greenblatt</term>
<term>Guideline</term>
<term>High probability</term>
<term>High risk</term>
<term>Hnpcc</term>
<term>Human genetics</term>
<term>Human mutation</term>
<term>Iarc</term>
<term>Inactivating mutations</term>
<term>Lake champlain cancer research organization</term>
<term>Lifetime risk</term>
<term>Likelihood ratio</term>
<term>Likely explanation</term>
<term>Lower limit</term>
<term>Mcgill university</term>
<term>Medical research</term>
<term>Missense substitutions</term>
<term>Mlh1</term>
<term>Multiple lines</term>
<term>Mutat</term>
<term>Mutation</term>
<term>Mutation carrier</term>
<term>Netherlands cancer institute</term>
<term>Odds ratios</term>
<term>Other genes</term>
<term>Other risk factors</term>
<term>Other types</term>
<term>Ovarian</term>
<term>Ovarian cancer</term>
<term>Pathogenic</term>
<term>Pathogenic mutation</term>
<term>Pathogenicity</term>
<term>Polygenic factors</term>
<term>Population risk</term>
<term>Posterior odds</term>
<term>Posterior probability</term>
<term>Predictive testing</term>
<term>Predictive values</term>
<term>Proband</term>
<term>Queensland institute</term>
<term>Research council</term>
<term>Residual</term>
<term>Residual risk</term>
<term>Risparmio firenze</term>
<term>Routine screening</term>
<term>Second family member</term>
<term>Segregation analysis</term>
<term>Sequence changes</term>
<term>Sequence conservation</term>
<term>Sequence variant</term>
<term>Sequence variants</term>
<term>Sequence variations</term>
<term>Steering committee</term>
<term>Such variants</term>
<term>Surveillance guidelines</term>
<term>Susceptibility</term>
<term>Syndrome</term>
<term>Systematic review</term>
<term>Tavtigian</term>
<term>Test result</term>
<term>Triple assessment</term>
<term>Tumor pathology</term>
<term>Uncertain variants</term>
<term>Variant</term>
<term>Variant result</term>
<term>Variant segregates</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Cancer</term>
<term>Base de données</term>
<term>Génétique</term>
<term>Recherche médicale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Genetic testing of cancer susceptibility genes is now widely applied in clinical practice to predict risk of developing cancer. In general, sequence‐based testing of germline DNA is used to determine whether an individual carries a change that is clearly likely to disrupt normal gene function. Genetic testing may detect changes that are clearly pathogenic, clearly neutral, or variants of unclear clinical significance. Such variants present a considerable challenge to the diagnostic laboratory and the receiving clinician in terms of interpretation and clear presentation of the implications of the result to the patient. There does not appear to be a consistent approach to interpreting and reporting the clinical significance of variants either among genes or among laboratories. The potential for confusion among clinicians and patients is considerable and misinterpretation may lead to inappropriate clinical consequences. In this article we review the current state of sequence‐based genetic testing, describe other standardized reporting systems used in oncology, and propose a standardized classification system for application to sequence‐based results for cancer predisposition genes. We suggest a system of five classes of variants based on the degree of likelihood of pathogenicity. Each class is associated with specific recommendations for clinical management of at‐risk relatives that will depend on the syndrome. We propose that panels of experts on each cancer predisposition syndrome facilitate the classification scheme and designate appropriate surveillance and cancer management guidelines. The international adoption of a standardized reporting system should improve the clinical utility of sequence‐based genetic tests to predict cancer risk. Hum Mutat 29(11), 1282–1291, 2008. © 2008 Wiley‐Liss, Inc.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Australie</li>
<li>Canada</li>
<li>France</li>
<li>Italie</li>
<li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region>
<li>Angleterre</li>
<li>Angleterre de l'Est</li>
<li>Gueldre</li>
<li>Hollande-Septentrionale</li>
<li>Québec</li>
<li>Texas</li>
<li>Vermont</li>
</region>
<settlement>
<li>Amsterdam</li>
<li>Cambridge</li>
<li>Montréal</li>
<li>Nimègue</li>
</settlement>
<orgName>
<li>Université McGill</li>
<li>Université de Cambridge</li>
</orgName>
</list>
<tree>
<country name="États-Unis">
<region name="Texas">
<name sortKey="Plon, Sharon E" sort="Plon, Sharon E" uniqKey="Plon S" first="Sharon E." last="Plon">Sharon E. Plon</name>
</region>
<name sortKey="Greenblatt, Marc S" sort="Greenblatt, Marc S" uniqKey="Greenblatt M" first="Marc S." last="Greenblatt">Marc S. Greenblatt</name>
<name sortKey="Plon, Sharon E" sort="Plon, Sharon E" uniqKey="Plon S" first="Sharon E." last="Plon">Sharon E. Plon</name>
<name sortKey="Plon, Sharon E" sort="Plon, Sharon E" uniqKey="Plon S" first="Sharon E." last="Plon">Sharon E. Plon</name>
<name sortKey="Plon, Sharon E" sort="Plon, Sharon E" uniqKey="Plon S" first="Sharon E." last="Plon">Sharon E. Plon</name>
</country>
<country name="Royaume-Uni">
<noRegion>
<name sortKey="Eccles, Diana M" sort="Eccles, Diana M" uniqKey="Eccles D" first="Diana M." last="Eccles">Diana M. Eccles</name>
</noRegion>
<name sortKey="Easton, Douglas" sort="Easton, Douglas" uniqKey="Easton D" first="Douglas" last="Easton">Douglas Easton</name>
</country>
<country name="Canada">
<region name="Québec">
<name sortKey="Foulkes, William D" sort="Foulkes, William D" uniqKey="Foulkes W" first="William D." last="Foulkes">William D. Foulkes</name>
</region>
</country>
<country name="Italie">
<noRegion>
<name sortKey="Genuardi, Maurizio" sort="Genuardi, Maurizio" uniqKey="Genuardi M" first="Maurizio" last="Genuardi">Maurizio Genuardi</name>
</noRegion>
<name sortKey="Genuardi, Maurizio" sort="Genuardi, Maurizio" uniqKey="Genuardi M" first="Maurizio" last="Genuardi">Maurizio Genuardi</name>
</country>
<country name="Pays-Bas">
<region name="Hollande-Septentrionale">
<name sortKey="Hogervorst, Frans B L" sort="Hogervorst, Frans B L" uniqKey="Hogervorst F" first="Frans B. L." last="Hogervorst">Frans B. L. Hogervorst</name>
</region>
<name sortKey="Hoogerbrugge, Nicoline" sort="Hoogerbrugge, Nicoline" uniqKey="Hoogerbrugge N" first="Nicoline" last="Hoogerbrugge">Nicoline Hoogerbrugge</name>
</country>
<country name="Australie">
<noRegion>
<name sortKey="Spurdle, Amanda B" sort="Spurdle, Amanda B" uniqKey="Spurdle A" first="Amanda B." last="Spurdle">Amanda B. Spurdle</name>
</noRegion>
</country>
<country name="France">
<noRegion>
<name sortKey="Tavtigian, Sean V" sort="Tavtigian, Sean V" uniqKey="Tavtigian S" first="Sean V." last="Tavtigian">Sean V. Tavtigian</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008746 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008746 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:30C3DB41661CBDFE24A2E9FA25E30AC26F93A1B7
   |texte=   Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024